HomeSHTDF • OTCMKTS
add
Sinopharm Group Co Ltd
Previous close
$2.64
Year range
$2.30 - $3.50
Market cap
62.41B HKD
Avg Volume
214.00
P/E ratio
-
Dividend yield
-
Primary exchange
HKG
Market news
.INX
1.26%
1.00%
Financials
Income Statement
Revenue
Net income
(CNY) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 147.27B | 1.20% |
Operating expense | 7.19B | 3.80% |
Net income | 1.42B | -10.70% |
Net profit margin | 0.96 | -11.93% |
Earnings per share | — | — |
EBITDA | 3.91B | -13.51% |
Effective tax rate | 23.21% | — |
Balance Sheet
Total assets
Total liabilities
(CNY) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 48.91B | 3.62% |
Total assets | 413.07B | 2.78% |
Total liabilities | 290.20B | 0.49% |
Total equity | 122.86B | — |
Shares outstanding | 3.12B | — |
Price to book | 0.11 | — |
Return on assets | 2.13% | — |
Return on capital | 4.25% | — |
Cash Flow
Net change in cash
(CNY) | Mar 2024info | Y/Y change |
---|---|---|
Net income | 1.42B | -10.70% |
Cash from operations | -47.48B | -16.68% |
Cash from investing | 256.12M | -38.43% |
Cash from financing | 22.15B | 4.94% |
Net change in cash | -25.07B | -30.76% |
Free cash flow | -24.53B | -79.75% |
About
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Founded
2003
Website
Employees
115,959